Papers

Research literature with structured metadata.

Trials

Registered studies by status, phase, and compound.

Topics

Indications and themes psychedelics are researched for.

Compounds

Evidence across molecules with rich data.

Countries

Regulation, access, and research activity by region.

Stakeholders

Organizations shaping the space across research, policy, and funding.

People

Investigators, clinicians, and authors with mapped output.

Courses

Training programs and certifications across modalities.

Events

Conferences, workshops, and convenings by date and focus.

Results

Compare outcome data across trials and publications.

Research Snapshot

One-page overview of trials, participants, papers, and research networks.

Clinical Guidelines

Trial-anchored manuals and protocol guidance with competency mapping.

Research recaps

Monthly evidence summaries with key takeaways.

Map of research

Landscape view of trials, compounds, and outcomes.

Newsletter

Weekly or daily updates on trials, publications, analysis, and more.

Research Groups

Worldwide map of psychedelic research centres by region.

Road to Access

Science, regulation, and economics on the path to patient access.

Research Network

Interactive co-authorship map of psychedelic researchers.

Top papers

Find needles in the haystack of psychedelic research per topic.

AskBeta
Pricing

The intelligence layer for psychedelic research.

Company

  • About
  • Contact
  • Newsletter

Product

  • Feedback
  • Roadmap
  • Changelog
  • API
  • Partners
  • Clinical Guidelines

Legal

  • Privacy
  • Terms

© 2026 Blossom. All rights reserved.

Home/Research/LSD/Anxiety Disorders

LSD for Anxiety Disorders

141 papers and 9 clinical trials exploring lsd as a treatment for anxiety disorders.

Compoundclassic psychedelic

LSD

LSD is a classic psychedelic ergoline with high potency at microgram doses and an 8-12 hour duration of action, mediated primarily via 5-HT2A receptor agonism. Modern Phase IIb data in generalised anxiety disorder and FDA Breakthrough Therapy Designation for MM120 have reignited clinical development.

Full LSD profile
IndicationThe most common mental disorders, about 301 million people worldwide

Anxiety Disorders

Anxiety disorders are the most common mental health conditions in the world, yet for primary anxiety (generalised anxiety, social anxiety, panic) the psychedelic evidence is surprisingly thin. The clear front-runner is LSD: MindMed’s MM120 met its Phase 2b endpoint in generalised anxiety disorder and is now in two Phase 3 trials. Most other psychedelic anxiety data comes from cancer and end-of-life distress, a different problem covered on our palliative page, or is measured as a side effect of treating depression.

Full Anxiety Disorders profile

Academic Research

141 papers
Open Accessindividual

Psychedelic-assisted therapy: a survey on the clinical methods of Swiss physicians

This survey study (n=41) examined how Swiss physicians provide psychedelic-assisted therapy under legal exemptions, mainly for depression, anxiety, PTSD and chronic pain. It found wide variation in practice, with psilocybin, MDMA and LSD commonly used, music often played during sessions, and adverse effects usually including disorientation, feeling cold, anxiety and nausea.

Published
May 20, 2026
Journal
Therapeutic Advances in Psychopharmacology
Authors
Beichmann, K., Catzeflis, P., Aicher, H. D., Seragnoli, F., Calder, A., Amrani, A., Hasler, G.
Open Accessindividual

Age moderates the relationship between psychedelics use and mental health in naturalistic settings

This cross-sectional survey (n=1,088) found that age significantly moderates the relationship between lifetime psychedelic use and mental health, with classic psychedelics such as psilocybin being associated with lower depression and anxiety in younger adults, but these benefits diminish with age and even reverse for anxiety in older participants.

Published
March 10, 2026
Journal
Research Square
Authors
Gregorio, G. D., Basset, S., Manmohan, H., Nixon, W. C., Pogaku, A., Zhou, J., Sanderson, D. J., Lengieza, M. L., Bocchio, M.
Open Accessindividual

It's all about the relationship: The caregiver experience of supporting a person with advanced cancer going through an LSD microdosing trial

This secondary analysis of an RCT (n=15 interviews) found that caregivers of people with advanced cancer were generally supportive of participation in an LSD microdosing plus meaning-centred psychotherapy trial, though some were initially hesitant. It highlighted the bidirectional nature of patient-caregiver well-being, with the intervention seen as offering hope, easing existential distress, and strengthening their relationship.

Published
February 26, 2026
Journal
Palliative & Supportive Care
Authors
Cottam, F., Wells, A., Clayden, C., Reynolds, L.
Open Accessindividual

Efficacy and Safety of the Neuroplastogen TSND-201 for the Treatment of PTSD A Randomized Clinical Trial

In a multicentre, double‑blind, placebo‑controlled phase 2 trial of 65 adults with chronic PTSD, once‑weekly oral TSND‑201 produced significantly greater reductions in clinician‑rated PTSD severity (CAPS‑5; LS mean difference 9.64, P = .01) and improvements in self‑reported symptoms, functioning and depression versus placebo. TSND‑201 was generally well tolerated — common adverse events included headache, decreased appetite, nausea, dizziness and transient blood‑pressure increases — supporting its potential as a rapid‑acting, durable treatment for PTSD.

Published
February 18, 2026
Journal
JAMA Psychiatry
Authors
Jones, A., Warner-Schmidt, J., Kwak, H., Stogniew, M., Mandell, B., Ching, T. H., Stein, M. B., Kelmendi, B.
Open Accessindividual

LSD microdosing in major depressive disorder: results from an open-label trial

This open-label Phase IIa trial (n=19, 15 male) found that an 8-week regimen of microdosed LSD (8μg initially, then 6-20μg twice weekly) for major depressive disorder was well-tolerated with no serious adverse events or cardiac valvulopathy, achieved 59.5% reduction in MADRS scores sustained for six months, and had only one withdrawal due to anxiety.

Published
February 1, 2026
Journal
Neuropharmacology
Authors
Daldegan-Bueno, D., Donegan, C. J., Sumner, R. L., Forsyth, A., Evans, W. J., Alshakhouri, M., Reynolds, L. M, Roop, P., Ponton, R., Smith, T., Hoeh, N. R., Allen, N., Sundram, F., Menkes, D. B., Muthukumaraswamy, S.
Open Accessindividual

Effects of LSD and Psilocybin on Heart Rate in Patients Receiving Psychedelic Treatment for Depressive and Anxiety Disorders: A Retrospective Observational Study

In this retrospective study of 30 patients receiving LSD or psilocybin for treatment‑resistant depression or anxiety, LSD produced a delayed, sustained increase in heart rate peaking at 3–4 hours while psilocybin showed an earlier decline, with a significant time × substance interaction that persisted after adjusting for age and anxiety and no serious cardiovascular events observed. These preliminary findings suggest distinct temporal cardiovascular profiles for LSD versus psilocybin but should be interpreted cautiously given the retrospective design, small sample and dose imbalance.

Published
December 19, 2025
Journal
Psychology International
Authors
Cheng, M., Aboulafia-Brakha, T., Buchard, A., Boyanova Anastasova, R., Girani, L., Breitenmoser, A., Alaux, S., Mabilais, C., Amberger, C., Seragnoli, F., Furtado, L., Thorens, G., Zullino, D., Penzenstadler, L.

Clinical Trials

9 trials
Active not recruitingPhase III

A Phase 3 Trial of MM120 for Generalized Anxiety Disorder (Panorama)

This Phase III, multicenter, randomised, double-blind, placebo-controlled trial (n=250) will evaluate the efficacy and safety of oral MM120 (LSD D-Tartrate) compared to placebo in adults diagnosed with generalized anxiety disorder (GAD). The study aims to assess changes in anxiety levels, primarily measured by the Hamilton Anxiety Rating Scale (HAM-A) total score, over a 12-week treatment period, followed by a 40-week open-label extension. Participants aged 18 to 74 years with a confirmed GAD diagnosis and a minimum HAM-A score of 20 will be enrolled. The trial consists of three arms: one receiving a placebo, one receiving 50 µg of MM120, and another receiving 100 µg of MM120. The initial 12-week phase will involve randomised, single-dose administration, after which participants will have the opportunity for open-label treatment based on safety and symptom severity criteria during the extension phase. The study is set to begin in January 2025 and aims to complete by May 2027.

Started
January 29, 2025
Type
interventional
Blinding
double
Randomized
Yes
Registry ID
NCT06809595
Active not recruitingPhase III

A Phase 3 Trial of MM120 for Generalized Anxiety Disorder (Voyage)

This Phase III, multicenter, randomised, double-blind, placebo-controlled trial (n=200) will evaluate the efficacy and safety of oral MM120 (LSD D-Tartrate) compared to placebo in adults with Generalized Anxiety Disorder (GAD). The study aims to assess changes in anxiety levels, primarily measured by the Hamilton Anxiety Rating Scale (HAM-A), over a 12-week period, followed by a 40-week open-label extension. Participants aged 18 to 74 years with a confirmed diagnosis of GAD and a minimum HAM-A score of 20 will be enrolled. The trial consists of a 12-week treatment phase where participants will receive either a single dose of 100 µg MM120 or a placebo, followed by a 40-week extension phase allowing for open-label treatment based on safety and symptom severity criteria. The study will monitor participants for changes in anxiety symptoms and overall safety throughout the trial duration.

Started
December 11, 2024
Type
interventional
Blinding
double
Randomized
Yes
Registry ID
NCT06741228
CompletedPhase NA

Salivary Oxytocin as a Biomarker in Psychedelic Assisted Psychotherapy (PAP_OXT)

This observational pilot study (n=10) will examine salivary oxytocin levels during a single dose of LSD as part of psychedelic-assisted psychotherapy (PAP) for anxiety disorders or depression.

Started
August 5, 2024
Type
observational
Randomized
No
Registry ID
NCT06557239
RecruitingPhase II

Lysergic Acid Diethylamide (LSD) in Palliative Care (LPC)

Randomised, quadruple-blind, active-placebo controlled parallel trial (n=60) testing two oral LSD sessions (100 µg then 100/200 µg) versus low-dose LSD active-placebo (25 µg ×2) for psychosocial distress in patients with end-stage disease.

Started
September 1, 2023
Type
interventional
Blinding
quadruple
Randomized
Yes
Registry ID
NCT05883540
Not yet recruitingPhase II

A feasibility study of Psychedelic Microdosing-Assisted Meaning Centred Psychotherapy in advanced stage cancer patients (PAM Trial)

This double-blind, placebo-controlled feasibility trial (n=40) investigates Psychedelic Microdosing-Assisted Meaning-Centred Psychotherapy (PA–MCP) in advanced-stage cancer patients. Led by Dr Lisa Reynolds at The University of Auckland, the study evaluates LSD microdosing (starting at 8 µg, twice weekly for 6 weeks; 13 doses total) alongside Meaning-Centred Psychotherapy.

Started
June 1, 2023
Type
interventional
Blinding
single
Randomized
Yes
Registry ID
ACTRN12623000478617
CompletedPhase II

A Dose-Finding Study of MM-120 for the Treatment of Anxiety Symptoms

This is a Phase II, multi-centre, randomized, double-blind, parallel-group, dose-finding study to assess the effect of four doses of MM-120 (25, 50, 100 or 200 μg LSD freebase-equivalent) for the treatment of anxiety symptoms in subjects diagnosed with generalized anxiety disorder (GAD).

Started
June 27, 2022
Type
interventional
Blinding
quadruple
Randomized
Yes
Registry ID
NCT05407064

Explore further

Search all LSD papers Search all Anxiety Disorders trials Full LSD profile Full Anxiety Disorders profile